A clinical trial at UT Southwestern Medical Center aims to determine whether adding the hormone leptin to standard insulin therapy might help control the tumultuous blood-sugar levels of people with type 1 (insulin-dependent) diabetes...
From now through January 31, 2011, The New-York Historical Society will present the exhibition Breakthrough: The Dramatic Story of the Discovery of Insulin, recalling the desperate fight for life that used to be waged by juvenile diabetes patients, and commemorating the events of 1921 that inaugurated a new era of hope for them and their families.
Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes.
The NEET (Naturlose® Efficacy Evaluation Trial) data showed a significant drop in Hemoglobin A1c (HbA1c) levels among patients treated with D-tagatose....
My favorite thing about my Freestyle Freedom Lite Blood Glucose Monitor is not the size of the monitor itself, or the fact that it requires such a tiny sample of blood. I favor this meter because it allows me to test on places other than my fingertips. (I usually use my forearm.) This is important to me because as a mother of three little boys, my hands are always working, preparing meals and snacks, and cleaning.
Following an ongoing FDA review of the diabetes drug Avandia (rosiglitazone) the FDA will require that GlaxoSmithKline (GSK) develop a restricted access program for Avandia under a risk evaluation and mitigation strategy, or REMS. Under the REMS, Avandia will be available to new patients only if they are unable to achieve glucose control on other medications and are unable to take Actos (pioglitazone), the only other drug in this class...
This week at the 46 th Annual Meeting of the European Association for the Study of Diabetes (EASD) Boehringer Ingelheim presented data from its linagliptin phase III clinical trial. Linagliptin belongs to the novel class of DPP-4 inhibitors and is currently...
More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77 percent of physicians estimate that in reality this number could be as high as six doses*, according to the Global Attitudes of Patients...
Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data demonstrate up to four times lower day-to-day variability in the total metabolic effect compared to insulin glargine (Lantus) in people with type 1 diabetes. The data were presented at the 46th Scientific Sessions of the European Association for the Study of Diabetes (EASD)...
Biodel Inc. researchers presented results of a clinical study evaluating a new pH-neutral formulation of Linjeta(TM) (VIAject(R)) at the 46th annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm today. Dr. Tim Heise (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues reported that...
Sanofi-aventis announced the upcoming launch of the blood glucose monitoring (BGM) devices BGStar and iBGStarTM, developed by sanofi-aventis and its partner AgaMatrix.
Due to their convenience, accuracy and ease-of-use, BGStar and iBGStarTM will help the decision-making process for people with diabetes and their healthcare professionals...